Sanofi (SNY), Regeneron (REGN) Receive EC Marketing Approval for ZALTRAP
Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Commission (EC) has granted marketing authorization in the European Union for ZALTRAP 25mg/ml concentrate for solution for infusion in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy in adults with metastatic colorectal cancer (mCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen. This decision was based on the efficacy and safety results of the VELOUR Phase 3 trial.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Galapagos NV (GLPG) Announces Positive Top-Line Data from GLPG1837 Phase 1
- OncoGenex Pharma (OGXI) Phase 3 AFFINITY Trial Protocol Amendment Supported by EMA
- Vertex Pharma (VRTX) Announces Significant Progress in Development Efforts to Treat Cause of CF
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!